ALSO NOTED: NicOx gains $5M from Merck; King sells manufacturing facility; and much more...

> Merck has begun clinical trials to develop nitric oxide-donating antihypertensive agents, triggering a €5 million milestone payment to NicOx. Release 

> King Pharmaceuticals is selling a manufacturing facility in Michigan for $90 million. Release

> Genzyme says that a post-marketing study of Carticel demonstrated that it helped patients who had not benefited from procedures to repair knee cartilage damage. Release 

> Researchers at the University of Oregon say that an individual's capacity of short-term memory is a strong predictor of IQ and scholastic achievement. People with high IQs can think about more things at once. Release

And Finally... In an effort to boost biotech drug sales, some companies are putting a "satisfaction guaranteed" promise on their products. Article

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.